Oddo BHF maintains its 'neutral' rating on AstraZeneca shares, with a target price raised from 12,100 to 12,500 pence following the CMD (investor day).

The analyst reports that management expects to achieve revenues of $80 billion by 2030, which is extremely ambitious, given that the consensus forecast was $69.1 billion.

'This CMD has reminded the market of the extent of the company's pipeline. AZN undoubtedly has one of the finest clinical portfolios in the industry", the broker believes.


Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.